Diese Website ist nur für
 medizinisches Fachpersonal bestimmt.

Deciphera_Logo2025

Leitlinien: ESMO

Die European Society of Medical Oncology (ESMO) veröffentlicht eine klinische Behandlungsleitlinie mit Empfehlungen zur Diagnose, Behandlung und Follow-Up von gastrointestinalen Stromatumoren. Eine interaktive Grafik veranschaulicht die ESMO-Leitlinie für die Behandlung von fortgeschrittenen GIST mit den aufeinanderfolgenden Therapielinien. Melden Sie sich mit Ihrem DocCheck-Zugang an und erhalten Sie Zugriff auf dieses praktische Hilfsmittel zur Navigation durch die verschiedenen verfügbaren Therapielinien.

Sie sehen gerade einen Platzhalterinhalt von DocCheck. Um auf den eigentlichen Inhalt zuzugreifen, klicken Sie auf den Button unten. Bitte beachten Sie, dass dabei Daten an Drittanbieter weitergegeben werden.

Weitere Informationen
Inhalt entsperren Erforderlichen Service akzeptieren und Inhalte entsperren

Diese Website wurde von Deciphera® entwickelt und finanziert und ist nur für medizinisches Fachpersonal bestimmt.
Wenn Sie Deciphera® für weitere Informationen kontaktieren möchten, senden Sie bitte eine E-Mail an medicalinformation@deciphera.com

DCPH-P02512

Regorafenib5

Line of therapy
Third.

Indication
For oncotherapy in adults with unresectable or metastatic GIST who progressed on or are intolerant to prior treatment with imatinib and sunitinib.

Posology
160 mg (4 tablets of 40 mg) taken once daily for 3 weeks followed by 1 week off therapy. This 4-week cycle should continue as long as benefit is observed or until unacceptable toxicity occurs.

Key studies for regorafenib

LINK

CITATION

TITLE

PUBLICATION
Demetri GD, et al. Lancet. 2013;381(9863):295–302.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: an international, multicentre, prospective, randomised, placebo-controlled phase 3 trial (GRID).

PUBLICATION
Poole CD, et al. Gastric Cancer. 2015;18(3):627–634.
Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
PUBLICATION

Komatsu Y, et al. Int J Clin Oncol. 2015;20(5):905–912.

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.

Ripretinib6

Line of therapy
Fourth.

Indication
Treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.

Posology
Treatment with ripretinib should continue as long as benefit is observed or until unacceptable toxicity.

Key studies for ripretinib

LINK

CITATION

TITLE

PUBLICATION
Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
PUBLICATION
Bauer S, et al. Clin Cancer Res. 2021;27(23):6333–6342.
Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogeneous KIT/PDGFRA mutations in the phase III INVICTUS study.

Sunitinib4

Line of therapy
Second.

Indication
The treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.

Posology
50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (Schedule 4/2) a complete cycle of 6 weeks.

Key studies for sunitinib

LINK

CITATION

TITLE

PUBLICATION
Demetri GD, et al. Clin Cancer Res. 2012;18(11):3170–3179.
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Avapritinib3

Line of therapy.
All lines in patients with PDGFRA mutations.

Indication
As monotherapy for the treatment of adult patients with unresectable or metastatic GIST harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.

Posology
Treatment should be continued until disease progression or unacceptable toxicity.

Key studies for avapritinib

LINK

CITATION

TITLE

PUBLICATION
Kang YK, et al. Lancet Oncol. 2021;39(28):3128–3139.
Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study.

Imatinib2

Line of therapy
Usually first line.

Indication
The treatment of adult patients with KIT (CD 117) positive unresectable and/or metastatic GIST. (Also for adjuvant treatment after surgery).

Posology
In clinical trials, treatment with Glivec was continued until disease progression. At the time of analysis, the treatment duration was a median of 7 months (7 days to 13 months). The effect of stopping after achieving a response has not been investigated.

Key studies for imatinib

LINK

CITATION

TITLE

PUBLICATION
Blanke CD, et al. J Clin Oncol. 2008;26(4):626–632.
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
PUBLICATION
Raut CP, et al. JAMA Oncol. 2018;4(12):e184060.
Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial.
PUBLICATION
Joensuu H, et al. J Clin Oncol. 2020;38(15_suppl):11503–11503.
Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): survival analysis of a randomized trial after 10 years of follow-up.
PUBLICATION
Casali P, et al. J Clin Oncol. 2017;35(15):1713–1720.
Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup phase III randomized trial on imatinib at two dose levels.
PUBLICATION
Blay JY, et al. J Clin Oncol. 2007;25(9):1107–1113.
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
PUBLICATION
Kang YK, et al. Lancet Oncol. 2013;14(12):1175–1182.
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.

Bleiben Sie Up to Date!

Wir informieren Sie über neueste wissenschaftliche Informationen, interaktive Patientenfälle & Podcasts rund um die GIST-Therapie.

Jetzt Newsletter sichern